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ABSTRACT
Objective: One hundred thirty-one cases of postsurgical infections were reported in Southern Re-
gion of Brazil between August 2007 and January 2008. Thirty-nine (29.8%) cases were studied; this 
report describes epidemiological findings, species identification, antimicrobial susceptibility and 
clonal diversity of rapidly growing mycobacteria isolated in this outbreak. Methods: All 39 isolates 
were analyzed by Ziehl-Nielsen stained smear, bacterial culture and submitted to rpoB partial gene 
sequencing for identification. The isolates were also evaluated for their susceptibility to amikacin, 
cefoxitin, clarithromycin, ciprofloxacin, doxycycline, tobramycin and sulfamethoxazole. Results: 
Thirty-six isolates out of the confirmed cases were identified as Mycobacterium massiliense and the 
remaining three were identified as Mycobacterium abscessus, Mycobacterium chelonae and Myco-
bacterium fortuitum. All M. massiliense isolates were susceptible to amikacin (MIC90 = 8 μg/mL) 
and clarithromycin (MIC90 = 0.25 μg/mL) but resistant to cefoxitin, ciprofloxacin, doxycycline, to-
bramycin and sulfamethoxazole. Molecular analysis by pulsed-field gel electrophoresis clustered all 
36 M. massiliense isolates and showed the same pattern (BRA 100) observed in three other outbreaks 
previously reported in Brazil. Conclusions: These findings suggest a common source of infection for 
all patients and reinforce the hypotheses of spread of M. massiliense BRA100 in Brazilian hospital 
surgical environment in recent years. 
Keywords: mycobacteria, atypical; mycobacterium infections; microbiological analysis.
ria have been generally related to contaminated 
medical equipments, solutions and laboratory 
reagents.8,9 Strains resistant to disinfectants 
have also been isolated from endoscope wash-
er disinfector after decontamination with 2% 
glutaraldehyde solution.10 Since 2% glutaralde-
hyde is one of the basic compounds most wide-
ly used as a chemical disinfectant for surgical 
equipment in several countries, particularly for 
non-autoclavable devices, resistance to bioc-
ides have become a great concern in hospital 
practice.
In Brazil, the first reported outbreaks 
caused by M. chelonae-abscessus group spe-
cies were related to laser in situ keratomileusis, 
mesotherapy sessions and breast implant sur-
geries.11,12 Mycobacterium massiliense has been 
described as the main agent isolated during 
these recent RGM outbreaks in several Bra-
zilian states, mainly those that occurred after 
2004. Furthermore, in all described postsurgi-
cal outbreaks, a specific M. massiliense clone, 
named BRA100, has emerged as an opportun-
INTRODUCTION
Human infections after cosmetic procedures, 
surgery, postinjection and nipple piercing1,2 
by rapidly growing mycobacteria (RGM) have 
been described worldwide as mainly associated 
with Mycobacterium chelonae, Mycobacterium 
abscessus, Mycobacterium fortuitum and Myco-
bacterium smegmatis groups.3 These microor-
ganisms have already been isolated from soil, 
water treatment plants, hospital tap water and 
distilled water, and considered environmen-
tally adapted species.4 Some RGM strains have 
been described as being able to develop bio-
film and infections related to biofilm represent 
more than two-thirds of all infections caused 
by these organisms.5
Hospital outbreaks as well as isolated cases 
of RGM infections have been reported in dif-
ferent scenarios involving chronic lung disease, 
disseminated cutaneous infections and post-
surgical wound infections.6,7 Outbreaks and 
pseudo-outbreaks associated with these bacte-
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istic pathogen, usually causing postsurgical wound infec-
tions, including superficial abscesses and granulomas.13 The 
Brazilian Public Health Surveillance System has registered 
an overall of 1,937 confirmed cases of RGM postsurgical 
infections since 2001. Up to now, only three M. massiliense 
outbreaks have been reported in Brazil, all related to surgi-
cal site infections following video-assisted surgeries. Even 
though each of the three Brazilian M. massiliense outbreaks 
occurred in distant geographical regions (Northern, Central 
and Southeastern regions of Brazil), strains isolated from 
each outbreak were identified as clonal by molecular tech-
niques.2,13,14 We report a new postsurgical infection outbreak 
of M. massiliense in Curitiba, Brazil, which includes clini-
cal findings, microbiological investigation, and molecular 
typing by pulsed-field gel electrophoresis (PFGE) and rpoB 
partial gene sequencing.
MATERIAL AND METHODS
General aspects and microbiological procedures
From August 2007 to January 2008, 131 patients were sub-
mitted to surgical procedures at one of the seven major pri-
vate hospitals located in the city of Curitiba, in the South 
region of Brazil. All patients showed signs of postsurgical 
infections clinically suggestive of RGM, such as wound with 
local inflammation, presence of abscess, delayed wound 
healing and no response to the treatment commonly used 
in cutaneous infections. Out of the 131 patients, a sample of 
39 patients were collected by either biopsy or aspiration of 
abscesses fluids and were cultivated on Lowenstein-Jensen 
solid medium for up to four weeks at 37°C.15 A detailed his-
tory of patients was obtained by the Public Health Surveil-
lance System. We were not able to inspect environmental 
conditions such as sterilization measures or antiseptic meth-
od applied. This study was approved by the Internal Review 
Board, Hospital do Trabalhador Ethics Committee.
Species identification
Observation of the growth rate was taken as an evidence 
of RGM. Definitive confirmation and species identification 
was based on partial sequencing of the rpoB gene. Extrac-
tion of DNA from clinical isolates was carried out using the 
Kit Nuclisens Basic Nasba Diagnostics (bioMérieux) based 
on methods previously published.16 DNA amplification 
and sequencing of the PCR products was performed with 
primers MycoF (5’–GCA AGG TCA CCC CGA AGG G–3’) 
and MycoR (5’–AGC GGC TGC TGG GTG ATC ATC–3’), 
that amplify a 764 bp within the rpoB gene.17 PCR mixtures 
(50 μL) contained 5 μL of 10 X Taq buffer (included with Taq 
polymerase), 200 μM each deoxynucleoside triphosphate, 
2 mM MgCl2, 1 U of Taq DNA polymerase (Invitrogen), 
10 mmol of each primer (Invitrogen), 2 μL of the extracted 
DNA and ultrapure water. PCR mixtures were subjected to 
35 cycles of denaturation at 94°C for 30s, primer annealing 
at 64°C for 30s, and DNA elongation at 72°C for 90s. Every 
amplification program began with a denaturation step of 
95°C for 1 min and ended with a final elongation step 
of 72°C for 5 min. Amplicons were purified with PureLinkTM 
PCR purification kit (Invitrogen) and cycle-sequenced us-
ing the Big dye terminator kit v.3.1 according to the manu-
facturer’s instructions (Applied Biosystems) with the fol-
lowing program: 30 cycles of denaturation at 94°C for 10s, 
primer annealing at 50°C for 15s, and extension at 60°C for 
4 min. The cycling-sequenced products were purified by 
Big Dye XTerminatorTM Purification kit (Applied Biosys-
tems) and detected on an ABI Prism 3110 DNA Sequence 
Analyzer (Applied Biosystems). The resulting sequences 
were aligned with BioEdit software (version 7.0.5.3)18 using 
M. tuberculosis H37Rv (GenBank accession BX842574.1) 
as the reference sequence. The homology analysis was per-
formed by comparison of the consensus sequence obtained 
from each isolate with those deposited in the GenBank using 
the BLAST algorithm (Basic Local Alignment Search Tool, 
http://www.ncbi.nlm.nih.gov/BLAST).
Antimicrobial susceptibility test
All 39 isolates were evaluated for their susceptibility to ami-
kacin, cefoxitin, clarithromycin, ciprofloxacin, doxycycline, 
sulfamethoxazole and tobramycin as recommended by the 
Clinical and Laboratory Standards Institute.19 Staphylococ-
cus aureus ATCC 29213 was used as a control strain.
Pulsed-field gel electrophoresis analysis
All M. massiliense isolates were submitted to genotypic anal-
ysis by PFGE. One isolate of M. massiliense BRA 100 clone 
from a previous outbreak occurred in Rio de Janeiro state 
(CRM 0020) and two epidemiologically unrelated strains re-
covered from sputum samples in 2007 in Rio de Janeiro city 
(CRM 0270 and CRM 0273) were also included for com-
parison. The agarose plugs were first treated as previously 
described, and then digested with DraI (Promega).20,21 Aga-
rose gel (1%) was used to separate the restriction fragments 
in a CHEF-DRIII system (Bio-Rad Laboratories) with pulse 
times increasing from 1.6 to 21.3s over 22 hr at 14°C, at a 
voltage gradient of 6 V/cm and with included angle of 120°. 
The PFGE profiles generated were analyzed by a commer-
cial molecular analysis fingerprinting GelCompar software 
(Applied Maths). Fragments patterns were interpreted as 
previously described.22
RESULTS
Clinical findings and outbreak description
We studied 39 cases of post-surgical infection, which were 
confirmed by microbiological culture while 92 remained 
as suspected cases. The median age was 50 years old (range 
Monego, Duarte, Nakatani et al.
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24-87) and most patients (73.0%) were female. All patients 
showed abscesses only on the surgical site. One hospital 
concentrated 77% of the cases. The time from surgery to 
the manifestation of clinical signs ranged from 5 to 60 days. 
Most patients (n = 33; 84.6%) were treated with a combined 
antimicrobial therapy consisting of clarithromycin, amika-
cin and terizidone. The remaining patients received an initial 
treatment with clarithromycin, amikacin and minocycline. 
The majority of cases (n = 37; 94.9%) progressed to cure and 
two reported deaths were associated with RGM infection.
Species identification
Growth of the isolates was observed in less than seven days 
and Ziehl–Nielsen stained smears showed acid-fast bacilli. 
The organisms were identified as rapidly growing non-pig-
mented mycobacteria and pure culture isolates were used for 
molecular species identification. Analysis of the rpoB gene 
sequences of all isolates were identical and presented 100% 
similarity (695/695) to the sequence from M. massiliense 
strain INCQS 594 (GenBank accession number EU117207). 
One sequence was identical (695/695) to M. abscessus type 
strain P02 (GenBank accession number FJ590436.1). One 
isolate was similar (695/695) to the M. chelonae ATCC 
19237 type strain, retrieved from GenBank under the acces-
sion number AY262740.1. The other isolate had the similar 
sequence (695/695) to M. fortuitum type strain CIP 104534T 
(GenBank accession number AY147165.1). 
Antimicrobial susceptibility test
All M. massiliense isolates were susceptible to amikacin 
(MIC90 = 8 μg/mL) and clarithromycin (MIC90 = 0.25 μg/mL) 
but resistant to cefoxitin, doxycycline, sulfamethoxazole and 
tobramycin. Thirty-five M. massiliense isolates were cipro-
floxacin-resistant and a single isolate was characterized as 
susceptible. M. abscessus isolate was susceptible to amikacin 
(MIC = 8 μg/mL) and clarithromycin (MIC = 0.25 μg/mL) 
and intermediate to cefoxitin (MIC90 = 128 μg/mL). How-
ever, this isolate was resistant to ciprofloxacin, doxycycline, 
tobramycin and sulfamethoxazole. M. chelonae isolate was 
susceptible to clarithromycin (MIC = 0.25 μg/mL) and in-
termediate to amikacin (MIC = 32 μg/mL) and tobramycin 
(MIC = 16 μg/mL), but resistant to cefoxitin, ciprofloxacin, 
doxycycline and sulfamethoxazole. M. fortuitum isolate was 
susceptible to amikacin (MIC = 8 μg/mL), clarithromycin 
(MIC = 0.25 μg/mL) and ciprofloxacin (MIC = 16 μg/mL) 
but resistant to doxycycline, sulfamethoxazole and tobramy-
cin. This isolate presented intermediate resistance to cefoxi-
tin (MIC = 128 μg/mL).
Molecular pattern
PFGE analysis revealed that M. massiliense isolates present-
ed indistinguishable patterns and according to the criteria 
proposed by Tenover et al.22 these isolates were considered 
highly related and to belong to the same strain. The PFGE 
patterns were similar to those of the isolates recovered from 
a recent epidemic in Rio de Janeiro, Southeastern Brazil 
(strain CRM 0020, Figure 1).13 M. massiliense isolates ob-
tained from sputum samples (CRM 0270 and CRM 0273) 
showed no identical eletrophoretic patterns when compared 
to those isolates from Curitiba and Rio de Janeiro (Figure 2).
Figure 1: PFGE pattern of M. massiliense isolates from 
Curitiba outbreak. M, molecular size markers (Lambda 
DNA	concatemers	 ranging	 from	48.5	 to	1,018.5	kb);	 lane	1,	 
CRM-587; lane 2, CRM-591; lane 3, CRM-592; lane 4, CRM-593; 
lane 5, CRM-595, lane 6, CRM- 596; lane 7, CRM-598; lane 8, 
CRM-602	and	lane	9,	CRM-604.
Figure 2: Map of rapidly growing mycobacteria confirmed 
cases by the Brazilian Public Health Surveillance System 
from	2001	to	2008.	The	map	indicates	the	cities	of	Goiânia,	
Belém, Rio de Janeiro and Curitiba where outbreaks have been 
reported.
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DISCUSSION
The Brazilian Public Health Surveillance System has pre-
sented cases of RGM infections from 2001 to date. Since 
2001, a total of 1,937 confirmed cases were registered, with 
an evident increase of outbreaks in the period (Figure 3). 
However, there are only three reports of M. massiliense out-
breaks in Brazil, all related to surgical infection following 
video-assisted surgeries. 
This study reports the identification and molecular epi-
demiological features of a single clone of M. massiliense iso-
lated from a new outbreak of surgical site infections caused 
by RGM in Curitiba, Southern region of Brazil. Partial rpoB 
sequence analysis was considered discriminatory for identifi-
cation of M. massiliense clinical isolates described here, since 
we obtained the highest similarity index (100%) when com-
paring our sequences to that of the M. massiliense type strain. 
The rpoB partial sequencing and PFGE analysis confirmed 
the similarity of our isolates with those of previously report-
ed outbreaks in Brazil.2,13,14 The molecular patterns obtained 
suggest a common source of infection and spread of a single 
clone of M. massiliense in different regions of the country.
There were some limitations in this study. First a re-
call bias might have occurred since only 39 cases were in-
cluded causing the reduced availability of other strains for 
analysis. Additionally, the lack of standardized procedures 
or protocols for isolation of RGM from surgical supplies 
made it difficult to determine the infection sources and its 
relation with surgical devices and equipments. Since no 
environmental isolates were obtained, we were not able 
to definitely identify the source of the infection. In this 
outbreak surgical equipments were disinfected by immer-
sion in 2% glutaraldehyde and were used in different hos-
pitals by different surgical teams that brought along their 
own instruments and performed surgeries in other cities 
and states. Inspections made by public health authorities 
evidenced that the disinfection protocol was unsettled by 
some of the hospitals in different ways. Thus, strictly moni-
toring concerning disinfection in 2% glutaraldehyde solu-
tion may explain why some hospitals in Curitiba have not 
had cases of surgical infections caused by RGM.
The sources of the infections for the surgical cases have 
not been identified in the first outbreak, in Northern Brazil. 
Patient procedures were performed by different surgeons, 
who used their own laparoscopic equipment, referred to 
be disinfected by immersion in 2% glutaraldehyde between 
surgeries and which were used in different hospitals.2 Incon-
sistencies in equipment cleaning, glutaraldehyde concentra-
tions, or contact times were suggested as the cause of the 
M. massiliense strain selection. The disinfection procedure 
used in arthroscopic and laparoscopic surgeries in Central 
Brazil outbreak was also performed by immersion in 2% 
glutaraldehyde. According to inspections made by public 
health authorities, the disinfection protocol was incorrectly 
implemented in some hospitals. So, inadequate aseptic tech-
niques during surgeries could have been the possible cause.13 
In the Southeastern outbreak, all hospitals that presented 
cases of M. massiliense infection used 2% alkaline glutaral-
dehyde solution to sterilize surgical instruments. Interest-
ingly, all M. massiliense isolates consistently presented toler-
ance to 2% glutaraldehyde.14 The authors suggested that 2% 
glutaraldehyde tolerance may partially explain the occur-
rence of outbreaks in three different regions in Brazil.
Based on reported RGM outbreaks, potential source of 
infection was either the lack of adequate disinfection proce-
dures (that could result in biofilm formation) or resistance 
to common disinfectants, or even both. Biofilms have been 
described in a high number of human infections, especially 
those related to biomaterials.23 Although biofilm formation 
may contribute to tolerance to biocide solutions,24 biofilm 
itself could not explain the single clone found on differ-
ent time periods in distinct Brazilian regions.13 However, 
since a significant relationship between biofilm develop-
ment ability and clinical infection has been experimentally 
demonstrated, biofilm development may be an important 
pathogenic risk factor for RGM, contributing to develop-
ment of human infections.25 Moreover, biofilms are a well-
known form of bacterial resistance against antibiotics,26 
and therefore the facility to develop these structures can 
explain treatment failures.27
Non-tuberculosis mycobacteria are often resistant to 
standard antituberculosis drugs and can be very difficult to 
treat. If RGM infection is identified and treated early, ade-
quate recovery is possible, otherwise death can ensue. In this 
report, 33 patients (n = 39, 84.6%) were treated with a com-
bination of amikacin, clarithromycin and terizidone. Treat-
ment with multiple agents is preferable because of a high 
rate of relapse and emergence of drug resistance.28 Amikacin 
and clarithromycin exhibited the greatest activity against all 
RGM isolates in this study and demonstrated to be effec-
tive when used in a multidrug regimen. All M. massiliense 
isolates from Rio de Janeiro outbreak tested in vitro were 
susceptible to amikacin and clarithromycin and resistant to 
cefoxitin, ciprofloxacin and doxycycline;13 the same suscep-
tibility pattern observed in our isolates. Although no treat-
ment data was presented in the Rio de Janeiro outbreak, 
patients from the Central Brazil outbreak were successfully 
treated with a combination of clarithromycin and amikacin. 
After the occurrence of RGM outbreaks, the Brazilian 
Public Health Surveillance System recommended preven-
tive measures to reduce the infections in Brazilian hospitals. 
These measures include the discontinuation of chemical 
sterilization by immersion for invasive items used in ab-
dominal surgeries, conventional laparoscopic and plastic 
surgery. For disinfection of non-autoclavable equipments 
used in surgical procedures such as endoscopes, sterilization 
should be performed by ethylene oxide gas, hydrogen per-
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Figure 3: PFGE patterns of 36 M. massiliense isolates from Curitiba outbreak. Identical patterns clustered the isolates from 
surgical patients. Comparison was performed with a commercial software (Applied Maths). The percentages of similarity among 
the profiles were calculated using Dice coefficient. The PFGE patterns of M. massiliense isolated from Rio de Janeiro outbreak 
(CRM	0020)	and	two	epidemiologically	unrelated	strains	from	Rio	de	Janeiro	patients	(CRM	0270	and	CRM	0273)	were	included	
in the analysis. a Hn, mycobacterial isolate from patient who undergone surgery at hospital number n; b RJ, mycobacterial isolate 
collected from Rio de Janeiro city.
Isolates Hospitala,b Surgery date  Surgery/Source Gender Age
.0270	 RJ	 2007	 Sputum	 M	 71
.0273	 RJ	 2007	 Sputum	 M	 36
.583	 H1	 11/23/07	 Cholecystectomy	 F	 65
.584	 H1	 10/19/07	 Cholecystectomy	 F	 50
.587	 H1	 10/10/07	 Cholecystectomy	 F	 56
.591	 H1	 10/07/07	 Cadioplasty	 M	 56
.592	 H1	 11/22/07	 Cadioplasty	 F	 55
.593	 H2	 08/20/07	 Cholecystectomy	 M	 47
.595	 H1	 09/11/07	 Cadioplasty	 F	 45
.596	 H1	 11/21/07	 Cholecystectomy	 M	 68
.598	 H1	 11/07/07	 Cadioplasty	 M	 56
.602	 H1	 11/19/07	 Cholecystectomy	 F	 37
.604	 H2	 08/23/07	 Appendicetomy	 M	 29
.606	 H1	 10/26/07	 Cadioplasty	 F	 57
.607	 H1	 10/20/07	 Cholecystectomy	 F	 72
.608	 H1	 11/13/07	 Cadioplasty	 F	 58
.609	 H3	 11/09/07	 Bariatric	surgery	 F	 34
.610	 H1	 10/19/07	 Myomectomy	 F	 36
.611	 H2	 10/13/07	 Bariatric	surgery	 M	 62
.612	 H1	 10/10/07	 Cadioplasty	 M	 77
.613	 H1	 10/09/07	 Oophoroplasty	 F	 28
.614	 H4	 10/29/07	 Bariatric	surgery	 M	 32
.615	 H2	 10/29/07	 Bariatric	surgery	 M	 38
.616	 H1	 11/12/07	 Cholecystectomy	 F	 54
.617	 H2	 08/24/07	 Appendicetomy	 M	 49
.618	 H1	 10/24/07	 Cadioplasty	 F	 32
.585	 H1	 12/05/07	 Herniorrhaphy	 M	 54
.588	 H2	 10/24/07	 Gastroplasty	 M	 50
.590	 H1	 11/05/07	 Cadioplasty	 M	 56
.597	 H1	 11/19/07	 Cholecystectomy	 M	 65
.599	 H1	 10/08/07	 Cholecystectomy	 M	 81
.600	 H1	 09/19/07	 Pyeloplasty	 F	 50
.601	 H1	 11/14/07	 Cholecystectomy	 F	 24
.605	 H1	 11/24/07	 Cholecystectomy	 M	 87
.603	 H1	 11/21/07	 Cadioplasty	 F	 43
.619	 H1	 11/06/07	 Thoracic	 F	 26 
   Simpathetomy
.0020	 RJ	 2006	 Cholecystectomy	 F	 56
.306	 H1	 11/22/07	 Gastroplasty	 F	 47
.308	 H1	 10/28/07	 Cholecystectomy	 F	 39
Dice Index (%)
M. massiliense outbreak in surgical sites
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oxide plasma or low-temperature steam with formaldehyde 
gas. Since these measures have been adopted by the hospitals 
no additional case of RGM infection was registered by the 
Brazilian Public Health Surveillance System. 
The obtained results suggest that a single M. massiliense 
clone might be responsible for the infections that have oc-
curred in Northern, Central and Southeastern regions of 
Brazil and reinforce the concept of M. massiliense BRA100 
as an emergent pathogen in Brazilian hospital surgical en-
vironment.
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